22:14 , Feb 21, 2019 |  BC Extra  |  Company News

Management tracks: Mirati, Verastem, RedHill

Oncology company Mirati Therapeutics Inc. (NASDAQ:MRTX) named Faheem Hasnain as chairman. He succeeds Rodney Lappe, who is retiring but will remain a consulting adviser. Hasnain is executive chairman of Gossamer Bio Inc. (NASDAQ:GOSS), which raised...
19:54 , May 25, 2018 |  BioCentury  |  Emerging Company Profile

Universal ambitions

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development. Emergex launched in 2016 with IP...
21:32 , Sep 29, 2017 |  BC Week In Review  |  Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
23:18 , Sep 25, 2017 |  BC Extra  |  Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
20:20 , Mar 2, 2017 |  BC Week In Review  |  Financial News

Midatech Pharma secures debt financing

On Feb. 27, nanomedicine company Midatech Pharma plc (LSE:MTPH; NASDAQ:MTP) obtained a £6 million ($7.4 million) senior secured loan facility from Silicon Valley Bank which matures in June 2020. Midatech plans to draw down a...
17:15 , Dec 9, 2016 |  BC Week In Review  |  Company News

Amryt, Aegerion deal

Aegerion granted Amryt exclusive rights to market Lojuxta lomitapide in the European Economic Area (EEA), Middle East and North Africa (MENA), Israel and Turkey. Aegerion is eligible for milestone payments, plus royalties. Amryt will be...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Financial News

Midatech Pharma completes placing

Midatech Pharma plc (LSE:MTPH; NASDAQ:MTP), Abingdon, U.K.   Business: Drug delivery, Cancer, Endocrine/Metabolic   Date completed: 2016-10-11   Type: Placing   Raised: L16 million ($19.9 million)   Shares: 14.5 million   Price: 110p   Shares...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Financial News

Midatech Pharma proposes private placement

Midatech Pharma plc (LSE:MTPH; NASDAQ:MTP), Abingdon, U.K.   Business: Drug delivery, Cancer, Endocrine/Metabolic   Date announced: 2016-10-11   Type: Private placement   To be raised: Up to L1.9 million ($2.4 million)   Shares: 1.8 million...
07:00 , Oct 11, 2016 |  BC Extra  |  Financial News

Nanomedicine play Midatech raises L16M

Midatech Pharma plc (LSE:MTPH; NASDAQ:MTP) raised L16 million ($19.9 million) through the sale of 14.5 million shares at 110p in an oversubscribed placing. The company plans to raise an additional L2 million ($2.5 million) in...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

MTX102: Phase Ia started

Midatech began an open-label, European Phase Ia trial to evaluate 3 doses of MTX102 given intradermally via microneedles 4 weeks apart in 8 Type I diabetics with residual endogenous insulin production. Midatech Pharma plc (LSE:MTPH;...